Genmab A/S GMAB 深 滬
等待開盤 10-28 09:30:00 美东时间
44.67
-0.015
-0.03%
華盛通- 最 高44.99
- 今 開44.41
- 成交量 492.91万股
- 最 低 43.98
- 昨 收 44.685
- 總市值 2746.77万
- 52周最高 45.445
- 市盈率 靜 28.99
- 換手率 0.80%
- 52周最低 23.62
- 委 比 -25.65%
- 總股本 0.01亿
- 歷史最高 49.07
- 量 比 0.77
- 振 幅 2.26%
- 歷史最低 16.24
- 每 手 1
- 風險率 3.65%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅101.01%！Stifel上调ORIC Pharmaceuticals目标价至18美元，维持"买入"评级
今日重点评级关注：Stifel：维持ORIC Pharmaceuticals"买入"评级，目标价从14美元升至18美元；花旗：维持Liberty Energy"买入"评级，目标价从27.5美元升至28美元
10-27 12:30
Genmab's Encouraging Oncology Data Boosts Investor Optimism
Biotechnology company Genmab A/S (NASDAQ:GMAB) delivered encouraging clinical updates for its investigational bispecific antibody petosemtamab across two major solid tumor types at the European Society for Medical Oncology Congress 2026, while securing a new clinical oncology partnership with Incyte...
10-26 23:08
港股通创新药ETF鹏华(159286)标的指数红盘向上，ESMO重磅数据和三季报披露催化板块行情
消息面上，Genmab美国存托凭证在卵巢癌药物试验达标后大幅上涨，此前，这家制药公司表示，其用于治疗卵巢癌的实验性药物在一项后期临床试验中达到了主要终点和关键次...
10-26 10:09
美股周涨跌榜 | 软件股集体霸榜！Braze周升56.4%，获Salesforce溢价收购；云安全公司Zscaler周内升逾两成
软件股集体霸榜！Braze周升56.4%，获Salesforce溢价收购；云安全公司Zscaler周内升逾两成，HubSpot大涨17%，Check Point软件升15%>>
10-24 10:58
Genmab’s Phase 3 RAINFOL-02 Trial Meets Primary PFS And Key Secondary OS Endpoints, Demonstrating A Statistically Significant And Clinically Meaningful Improvement For Rina-S In Platinum-Resistant Ovarian Cancer
Phase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) with rinatabart sesutecan (Rina-S®) compared to investigator’s choice chemotherapy Results demonstrated statistically significant and clinically meaningful im...
10-23 23:57
Genmab A/S(GMAB)股票10月23日盘中上涨7.86%：释放什么信号？
• Genmab 关于 rinatabart sesutecan 的 3 期临床试验成功达到主要和次要终点。 • 稳定的 DARZALEX 特许权使用费收入以及 epcoritamab 的积极结果提振了机构投资者信心。 • Genmab 报告年营收达 37.2 亿美元，分析师平均目标价为 45.02 美元。
10-23 16:16
Genmab A/S Stock (GMAB) Moved Up by 7.86% on Oct 23: A Full Analysis
• Genmab's Phase 3 trial for rinatabart sesutecan successfully met primary and secondary endpoints. • Steady DARZALEX royalty revenue and positive epcoritamab results boost institutional investor confidence. • Genmab reports $3.72B annual revenue and an average analyst price target of $45.02.
10-23 16:15
BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer
BioNTech collaborates with Gilead Sciences to evaluate pumitamig combined with sacituzumab govitecan for treating PD-L1 low or negative triple-negative breast cancer (TNBC). The global Phase 3 ROSETTA Breast-01 trial aims to improve outcomes by replacing chemotherapy with this novel combination, reflecting the evolving standard of care. Pumitamig, a bispecific immunomodulator targeting PD-L1 and VEGF-A, is being tested in multiple solid tumors, w...
10-22 10:45
2026 ESMO|再鼎、石药、GSK等披露关键数据
（来源：药研网） 2026 ESMO官网已公布常规摘要全文，小编重点整理了再鼎、GSK、默沙东等公司的关键数据。 1 再鼎ZL-1310联合疗法 本文官...
10-20 17:40
